Register Free
Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Diabetes / Metabolic Women's Health Rheumatology Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Trial Radar • ClinicalTrials.gov • Registry-linked

Trial Radar

2236 clinical trials with phase, status, specialty and registry links, summarised for rapid clinical review.

2236 recruiting AI clinical summaries
Explore Trial Collections Follow research updates
All Phases Phase I Phase II Phase III Phase IV
Therapeutic Area: All Cardiology / Cardiovascular Dermatology Diabetes / Metabolic Gastroenterology Haematology Infectious Disease Men's Health Mental Health / Psychiatry Nephrology Neurology Oncology Rare Diseases
🔬
Trial Radar

Clinical Trial Intelligence

● Recruiting Phase III Oncology
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
What is being tested: T-DXd (trastuzumab deruxtecan) combined with rilvegostomig or as monotherapy, compared against standard-of-care gemcitabine plus cisplatin with durvalumab in treatment-naïve patients…
16 Apr 2026 NCT06467357
● Recruiting Oncology
Breast Cancer Evolution During Neoadjuvant Systemic Therapy
What is being tested: BELIEVE is a translational study collecting breast cancer tissue, blood, and imaging samples from patients receiving neoadjuvant systemic therapy (chemotherapy,…
16 Apr 2026 NCT06681064
● Recruiting Phase III Oncology
A Study of BGB-16673 Compared to Investigator’s Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
What is being tested: BGB-16673, a novel therapeutic agent, is being evaluated against standard investigator-selected treatments (idelalisib, bendamustine, or venetoclax—each combined with rituximab) in…
16 Apr 2026 NCT06846671
● Recruiting Oncology
Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
What is being tested: Ultomiris® (Ravulizumab), a C5 complement inhibitor, is being evaluated for safety outcomes in pregnant women and their offspring, including maternal…
16 Apr 2026 NCT06312644
● Recruiting Phase III Oncology
Study to Evaluate INCB123667 Versus Investigator’s Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
What is being tested: INCB123667, a targeted therapy, is being compared against standard chemotherapy regimens in patients with platinum-resistant ovarian cancer specifically selected for…
16 Apr 2026 NCT07214779
● Recruiting Phase III Oncology
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
What is being tested: Palazestrant (an oral selective oestrogen receptor degrader) combined with ribociclib (CDK4/6 inhibitor) versus the standard treatment of letrozole (aromatase inhibitor)…
16 Apr 2026 NCT07085767
active not recruiting Phase III Oncology
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
Ongoing access to darolutamide for prostate cancer patients who benefited from previous trials, with continued monitoring.
15 Apr 2026 NCT04464226
active not recruiting
SAPIEN 3 Ultra System PMCF
Edwards SAPIEN 3 Ultra valve reduces symptoms in patients with severe aortic stenosis, confirming safety and effectiveness in real-world use.
15 Apr 2026 NCT04555967
● Recruiting Phase III Neurology
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
DEEP SEA Study Summary LP352 tested against placebo to reduce seizures in children and adults with Dravet syndrome over 24 months.
15 Apr 2026 NCT06660394
active not recruiting Phase II
A Study of Intrathecal SHP611 in Children With Metachromatic Leukodystrophy
Spinal fluid injections of SHP611 tested to slow movement decline in children with metachromatic leukodystrophy.
15 Apr 2026 NCT03771898
active not recruiting Phase IV Oncology
RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)
Trial comparing radium-223 with standard hormone therapy for advanced prostate cancer spread to bones.
15 Apr 2026 NCT04597125
● Recruiting Phase II Oncology
Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Inobrodib combined with pomalidomide and dexamethasone shows promise in treating multiple myeloma that resists standard therapies.
15 Apr 2026 NCT07096778
● Recruiting Phase I Neurology
First in Human Safety and Ease of Use Assessment of 400mg Progesterone Callavid in Women With Luteal Phase Insufficiency
Early-stage trial testing safety and user experience of new vaginal progesterone device versus standard pessaries in women with luteal phase insufficiency.
15 Apr 2026 NCT07136922
● Recruiting Phase II Oncology
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
Treatment being tested: RO7198457 (an investigational targeted therapy) is being compared against watchful waiting in patients with detectable circulating tumor DNA (ctDNA) following surgical…
15 Apr 2026 NCT04486378
● Recruiting Phase I Oncology
Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer
Treatment being tested: SX-682 (a CXCR4 inhibitor) combined with apalutamide (an androgen receptor inhibitor) in men with metastatic castration-resistant prostate cancer, aiming to overcome…
15 Apr 2026 NCT07002320
● Recruiting Phase I Oncology
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
What is being tested: A dual immunotherapy combination of BNT324 (B7-H3 targeted antibody-drug conjugate) and BNT327 (PD-L1/VEGF bispecific antibody) to evaluate efficacy and safety…
15 Apr 2026 NCT06892548
● Recruiting Oncology
Real-world Evaluation of Patient Outcomes and Experiences With Ribociclib Early Adopters.
What is being tested: A real-world evaluation of ribociclib (CDK4/6 inhibitor) effectiveness, persistence, safety profile, treatment patterns, and patient-reported outcomes including adherence, satisfaction, and…
15 Apr 2026 NCT07243002
● Recruiting Respiratory / COPD / Asthma
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
What is being tested: Digital biomarkers and blood-based biomarkers are being evaluated for their ability to correlate with tau and amyloid PET imaging findings,…
15 Apr 2026 NCT06584357
● Recruiting Phase I Neurology
An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency
Treatment being tested: ECUR-506, a novel therapeutic intervention for neonatal-onset Ornithine Transcarbamylase (OTC) deficiency, the most common urea cycle disorder caused by defective ammonia…
15 Apr 2026 NCT06255782
● Recruiting Phase II Diabetes / Metabolic
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease
Intervention tested: Vicadrostat (a novel selective aldosterone synthase inhibitor) combined with empagliflozin (an SGLT2 inhibitor) in adults with progressive chronic kidney disease, building on…
15 Apr 2026 NCT06926660
● Recruiting Phase II Oncology
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
What is being tested: Autologous LN-145, a tumor-infiltrating lymphocyte (TIL) therapy administered to patients with metastatic non-small-cell lung cancer (NSCLC) in a phase 2…
15 Apr 2026 NCT04614103
● Recruiting Phase II Oncology
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
What is being tested: BNT327 (an investigational agent) combined with chemotherapy and other experimental drugs in first-line treatment of non-small cell lung cancer (NSCLC),…
15 Apr 2026 NCT06712316
● Recruiting Phase II Diabetes / Metabolic
Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease
What is being tested: KL1333, a novel therapeutic agent, is being evaluated for its efficacy in reducing disease manifestations of primary mitochondrial disease (PMD),…
15 Apr 2026 NCT05650229
● Recruiting Phase I Cardiology / Cardiovascular
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
What is being tested: BGB-16673 is a novel investigational agent being evaluated in a dose-escalation and expansion study to determine safe and effective dosing…
15 Apr 2026 NCT05006716
● Recruiting Phase II Cardiology / Cardiovascular
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
What is being tested: Pelacarsen (TQJ230), a subcutaneous antisense oligonucleotide that lowers lipoprotein(a), is being evaluated against placebo to determine whether reducing Lp(a) levels…
15 Apr 2026 NCT05646381
● Recruiting Oncology
Met Non Small Cell Cancer Registry (MOMENT)
What is being tested: MOMENT is a prospective multi-national disease registry collecting standardized longitudinal data on non-small cell lung cancer (NSCLC) treatment patterns and…
15 Apr 2026 NCT05376891
● Recruiting Phase IV Oncology
Acalabrutinib Monotherapy vs Investigator’s Choice of Treatment in Patients With CL Leukaemia and Heart Failure
What is being tested: Acalabrutinib monotherapy (100 mg twice daily) versus investigator's choice of alternative treatment in a Phase IV randomised trial evaluating safety…
15 Apr 2026 NCT06651970
● Recruiting Phase III Oncology
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
Treatment Being Tested: Tarlatamab (a DLL3-targeting bispecific antibody) versus placebo administered after standard chemoradiotherapy in patients with limited-stage small-cell lung cancer, with primary efficacy…
15 Apr 2026 NCT06117774
● Recruiting Phase III Oncology
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
What is being tested: Sonrotoclax (a novel BCL2 inhibitor) combined with monoclonal antibodies (obinutuzumab or rituximab) versus the established standard treatment venetoclax plus rituximab…
15 Apr 2026 NCT06943872
● Recruiting
Influence of Perfluorocarbon Liquid (LIQUID) During Pars Plana Vitrectomy on Retinal Vessel Displacement in Primary Macula-involving Rhegmatogenous Retinal Detachment
Study examines whether using perfluorocarbon liquid during retinal detachment surgery affects post-operative retinal vessel shifting and vision outcomes.
14 Apr 2026 NCT07027098
● Recruiting Phase I / Phase II
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
Early-stage trial testing a new oral drug (nuvisertib) for safety and effectiveness in myelofibrosis patients.
14 Apr 2026 NCT04176198
active not recruiting Phase II Oncology
Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression
FAIM Trial Summary Adding ipatasertib to fulvestrant and palbociclib may improve survival in advanced hormone-receptor positive breast cancer patients without early treatment response.
14 Apr 2026 NCT04920708
active not recruiting Phase II Oncology
A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine
Adults who previously tolerated brigimadlin continue taking tablets every three weeks to assess long-term safety and tumour response.
14 Apr 2026 NCT06619509
● Recruiting
Clinical and Molecular Studies in Families With Inherited Eye Disease
Study identifying genetic causes of inherited eye diseases through clinical examination, electrical eye testing, and blood/saliva genetic analysis.
14 Apr 2026 NCT02771236
active not recruiting Oncology
Does Screening With the Galleri Test in the NHS Reduce the Likelihood of a Late-stage Cancer Diagnosis in an Asymptomatic Population? A Randomised Clinical Trial
Blood test screening alongside standard NHS testing detected more early-stage cancers and fewer late-stage cancers in asymptomatic adults.
14 Apr 2026 NCT05611632
● Recruiting Phase II
Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Study
Long-term safety and efficacy study of lunsekimig (a new treatment) in adults with poorly controlled chronic rhinosinusitis with nasal polyps over 52 weeks.
14 Apr 2026 NCT06914908
● Recruiting Respiratory / COPD / Asthma
Eosinopenia in Severe COPD Exacerbation
What is being tested: This observational study investigates the causes and recovery patterns of eosinopenia (abnormally low blood eosinophil counts) in patients hospitalised with…
14 Apr 2026 NCT06188065
● Recruiting Phase III Respiratory / COPD / Asthma
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
What is being tested: Tezepelumab, a thymic stromal lymphopoietin (TSLP) inhibitor monoclonal antibody, is being evaluated for efficacy and safety in adult patients with…
14 Apr 2026 NCT06883305
● Recruiting Phase IV Cardiology / Cardiovascular
Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress
What is being tested: Oral anticoagulation therapy compared to no anticoagulation for stroke prevention in patients with stress-induced transient atrial fibrillation who have additional…
14 Apr 2026 NCT03968393
● Recruiting Phase III Cardiology / Cardiovascular
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
Drug being tested: Mavorixafor, a CXCR4 antagonist, is being evaluated for efficacy, safety and tolerability in patients with chronic neutropenic disorders (both congenital and…
14 Apr 2026 NCT06056297
● Recruiting Phase I Oncology
A Phase 1/1b Study of IAM1363 in HER2 Cancers
What is being tested: IAM1363, a novel therapeutic agent, is undergoing Phase 1/1b evaluation to assess its safety profile and preliminary efficacy in patients…
14 Apr 2026 NCT06253871
● Recruiting Phase III Oncology
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
What is being tested: Amivantamab (a bispecific antibody) combined with standard chemotherapy (mFOLFOX6 or FOLFIRI) versus the current standard treatment of cetuximab plus chemotherapy…
14 Apr 2026 NCT06662786
● Recruiting Phase III Oncology
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
What is being tested: Amivantamab (a bispecific antibody targeting EGFR and MET) combined with FOLFIRI chemotherapy, compared to the standard treatment of cetuximab/bevacizumab with…
14 Apr 2026 NCT06750094
● Recruiting Phase I Oncology
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
Treatment Being Tested: Gedatolisib (a PI3K/mTOR inhibitor) combined with darolutamide (an androgen receptor antagonist) in metastatic castration-resistant prostate cancer, with dose-finding and efficacy evaluation…
14 Apr 2026 NCT06190899
● Recruiting Phase I Oncology
A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
What is being tested: A phase 1/2 dose-escalation study investigating the combination of two investigational drugs—Pasritamig (JNJ-78278343) and JNJ-86974680—to identify the optimal tolerated dose…
14 Apr 2026 NCT07319871
● Recruiting Phase I Oncology
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
What is being tested: (177Lu) rhPSMA-10.1 is a radioligand therapy targeting PSMA-expressing tumours in metastatic castrate-resistant prostate cancer, with evaluation of optimal dosing, safety…
14 Apr 2026 NCT05413850
● Recruiting Phase III Oncology
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
Treatment being tested: Pasritamig (a novel therapeutic agent) combined with docetaxel chemotherapy versus docetaxel alone in metastatic castration-resistant prostate cancer (mCRPC), with primary endpoint…
14 Apr 2026 NCT07225946
● Recruiting Phase I Oncology
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
What is being tested: A Phase 1b/2 dose-escalation study evaluating the combination of two investigational agents (JNJ-78278343 and JNJ-95298177) in prostate cancer, with Part…
14 Apr 2026 NCT07082920
● Recruiting Phase II Oncology
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
What is being tested: Long-term safety monitoring of enzalutamide in prostate cancer patients who are continuing to benefit from treatment in previous Astellas or…
14 Apr 2026 NCT02960022
● Recruiting Phase II Oncology
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
What is being tested: Amivantamab (a bispecific antibody targeting EGFR and MET) administered subcutaneously with recombinant human hyaluronidase in combination regimens, primarily for advanced/metastatic…
14 Apr 2026 NCT05498428